Prothena Corp Public PRTA
NASDAQ PRTA
$9.78 +0.18 (+1.87%)
As of: Sep 4, 2026 · 2:20 PM EDT

Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026)

Prothena Corp Public (PRTA) posted quarterly Cash from Financing Activities of -$6.9 million for Q1 2026, down 14370.83% year-over-year from N/an in Q1 2025, and down 40758.82% quarter-over-quarter from -$17000.0 in Q3 2025.

Analysis

Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026) Analysis & Trends

Prothena Corp Public's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities fell 14370.83% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$7.0 million (down 1150.3% YoY), while the FY2025 annual figure was -$139000.0, down 108.94% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$6.9 million, down from -$17000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $220.8 million in Q4 2022, with the low at -$6.9 million in Q1 2026.
  • The 5-year median for Cash from Financing Activities is $659500.0 (2023), against an average of $17.6 million.
  • The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 12351.49% in 2022, then sank 14370.83% in 2026.
  • Prothena Corp Public's Cash from Financing Activities stood at $220.8 million in 2022, then tumbled by 99.78% to $483000.0 in 2023, then plunged by 112.22% to -$59000.0 in 2024, then jumped by 71.19% to -$17000.0 in 2025, then sank by 40758.82% to -$6.9 million in 2026.
  • Business Quant data shows PRTA's Cash from Financing Activities at -$6.9 million in Q1 2026, -$17000.0 in Q3 2025, and -$74000.0 in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn -
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - 2.42 Bn
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - -273.15 Mn
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn 27.18 Mn
10 Prothena Corp Public 509.98 Mn 221.78 Mn - -15.57 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.57 Mn
Mar 31, 2026 -6.95 Mn
Sep 30, 2025 -17,000.00
Jun 30, 2025 -74,000.00
Mar 31, 2025 -48,000.00
Dec 31, 2024 -59,000.00
Sep 30, 2024 333,000.00
Jun 30, 2024 444,000.00
Mar 31, 2024 836,000.00
Dec 31, 2023 483,000.00
Sep 30, 2023 2.71 Mn
Jun 30, 2023 18.63 Mn
Mar 31, 2023 23.28 Mn
Dec 31, 2022 220.77 Mn
Sep 30, 2022 18.13 Mn
Jun 30, 2022 1.23 Mn
Mar 31, 2022 1.34 Mn
Dec 31, 2021 1.77 Mn
Sep 30, 2021 87.01 Mn
Jun 30, 2021 20.22 Mn